Expression and interaction mechanism of PAX6 in human non-small cell lung cancer

熊安洲; 陈菁; 曹艳; 胡小萍

doi:10.3969/j.issn.1007-3969.2014.08.008

您当前的位置：

首页 >

文章列表页 >

Expression and interaction mechanism of PAX6 in human non-small cell lung cancer

更新时间：2025-12-31

- Expression and interaction mechanism of PAX6 in human non-small cell lung cancer
- China Oncology Vol. 24, Issue 8, Pages: 604-609(2014)
- 作者机构：
  
  武汉市第一医院呼吸科,湖北,武汉,430022
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2014.08.008
  CLC：
- Published Online：07 November 2014，
  
  Published：07 November 2014
- 稿件说明：
移动端阅览
熊安洲,陈菁,曹艳,胡小萍. 非小细胞肺癌中PAX6表达及其对肿瘤细胞增殖与侵袭作用机制研究[J]. 中国癌症杂志, 2014, 24(8): 604-609.

熊安洲, 陈菁, 曹艳, et al. Expression and interaction mechanism of PAX6 in human non-small cell lung cancer[J]. China Oncology, 2014, 24(8): 604-609.
熊安洲,陈菁,曹艳,胡小萍. 非小细胞肺癌中PAX6表达及其对肿瘤细胞增殖与侵袭作用机制研究[J]. 中国癌症杂志, 2014, 24(8): 604-609. DOI： 10.3969/j.issn.1007-3969.2014.08.008.

熊安洲, 陈菁, 曹艳, et al. Expression and interaction mechanism of PAX6 in human non-small cell lung cancer[J]. China Oncology, 2014, 24(8): 604-609. DOI： 10.3969/j.issn.1007-3969.2014.08.008.

摘要

背景与目的：转录因子PAX6主要表达于胚胎期，不同肿瘤中PAX6呈现高表达，通过不同的信号通路发挥肿瘤抑制或促进作用。检测PAX6在非小细胞肺癌(non-small cell lung cancer，NSCLC)中的表达，通过RNAi下调其表达，研究PAX6对肿瘤细胞侵袭和增殖力以及cyclin E、p38表达水平的影响。方法：应用蛋白印记检测86例NSCLC肿瘤组织及癌旁配对组织以及2例细胞系中PAX6的表达情况。应用PAX6特异性siRNA序列，转染NSCLC细胞系A549，MTT法、Transwell小室、划痕实验检测转染前后细胞增殖、侵袭和迁移能力的对比。蛋白质印记法(Western blot)检测转染前后cyclin E及p38表达情况。结果：对比癌旁组织及正常人支气管上皮细胞16HBE，PAX6在NSCLC组织及A549细胞系中显著高表达。选取高效siRNA序列转染细胞系后，PAX6表达的下调抑制了肿瘤细胞的增殖及集落形成，G1期细胞比例增加，细胞侵袭及迁移力均下降。PAX6基因敲低细胞cyclin E及p38活性受到抑制，表达下调。结论：PAX6通过调控MAPK通路及cyclin E的表达加速肿瘤细胞的增殖、侵袭及迁移，是潜在的NSCLC诊疗靶点。

Abstract

Background and purpose: The transcription factor PAX6 is primarily expressed in embryos. PAX6 is also expressed in several tumors and plays oncogenic or tumor suppressor role. This study aimed to investigate the expression of PAX 6 in non-small cell lung cancer (NSCLC) tumor samples and cell lines; and evaluate the effects of PAX6 on the proliferation and invasion of tumor cells and the expression level of cyclin E and p38. Methods: Western blot was carried out to detect the PAX6 protein level in 86 NSCLC tumor tissues

paired adjacent normal tissues and 2 cell lines. PAX6 siRNA was transfected into human lung cancer A549 cell line. Anchorage-independent growth and invasiveness of tumor cells were measured by MTT and transwell cell invasion assay

respectively. Cyclin E and p38 protein level before and after transfection were detected by western blot. Results: Comparison with tumor adjacent tissues and normal human bronchial epithelial cells 16HBE

PAX6 in NSCLC tissues and A549 cell lines was significantly higher expression. After transfection with efficient sequence of PAX6 siRNA for A549 cell lines

the down expression of PAX6 inhibits tumor cell proliferation

the proportion of cells in G1 phase increased

the cell invasion and migration decreased remarkably. Cyclin E and p38 activity was inhibited in PAX6 knockdown cells. Conclusion: PAX6 accelerate cell cycle progression by activating cyclin E and p38. PAX6 is a potential target for diagnosis and therapy.

关键词

Keywords

references

Views

2073

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research on high-throughput detection of plasma cell-free DNA for targeted therapy-related genes screening and prognosis prediction in non-small cell lung cancer patients

Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications

A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis

Important clinical research progress in lung cancer in 2022

Research progress of ALK kinase domain drug resistance mutation and its future countermeasures

Related Author

Qiling DENG

Di SONG

Kexin XI

Xiaoting XIE

Xiaoyan WU

Wei ZHAO

Yicong LIN

Yue WANG

Related Institution

Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine

BSL-3 Laboratory(Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University

Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Oncology, Peking University International Hospital

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University

AI问答

⁰